182871-13-2

Upstream product

• 182871-02-9 2-(trimethylsilyl)ethyl 2,3-di-O-toluoyl-β-D-glucopyranoside 
• 117253-03-9 2-(trimethylsilyl)ethyl 4,6-O-benzylidene-β-D-glucopyranoside 
• 874-60-2 4-methyl-benzoyl chloride 
• 182871-08-5 2-(trimethylsilyl)ethyl 6-O-levulinoyl-2,3,4-tri-O-toluoyl-β-D-glucopyranoside 

Downstream Products

• 182871-32-5 2-(trimethylsilyl)ethyl O-(3-O-allyl-2,4-di-O-toluoyl-β-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-toluoyl-β-D-glucopyranoside 
• 182871-28-9 O-[(3-O-allyl-6-O-levulinoyl-2,4-di-O-toluoyl-β-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-toluoyl-α-D-glucopyranosyl)]trichloroacetamidate 
• 182871-24-5 2-(trimethylsilyl)ethyl O-(3-O-allyl-6-O-levulinoyl-2,4-di-O-toluoyl-β-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-toluoyl-β-D-glucopyranoside 

Relevant academic research and scientific papers

Design and synthesis of gentiohexaosyl derivatives for an ANP receptor antagonist, HS-142-1

A hexaosyl fragment of the major component of lipooligosaccharide HS- 142-1, O-(3-O-caproyl-β-D-glucopyranosyl)-(1→6)-[O-(β-D-glucopyranosy l)- (1→6)-O-(3-O-caproyl-β-D-glucopyranosyl)-(1→ 6)]2-D-glucopyranose (1), was efficiently synthesized by block synthesis. More stable analogs, O-(3-O- hexyl-B-D-glucopyranosyl)-(1→6)-[O-(B-D-glucopyranosyl)-(1→6)-O -(3-O-hexyl- β-D-glucopyranosyl)-(l→6)]2-D-glucopyranose (4) and O-(3-O-caproyl-2,4,6- tri-O-methyl-β-D-glacopyranosyl)-(1→6)-[O(2,3,4-tri-O-methyl-β -D- glucopyranosyl)-(1→6)-O-(3-O-caproyl-2,4-di-O-methyl-β-D-glucop yranosyl)- (1→6)]2-2,3,4-tri-O-methyl-D-glucopyranose (2), were also designed and synthesized in a similar manner.